Innovation in Central and Eastern Europe
The Life Sciences in Transition
This special issue explores an interdisciplinary topic that lies at the heart of Studies in Ethics, Law, and Technology. The life science industry is increasingly recognised as key sector in the growth and development of many economies. As it gains momentum, policymakers are confronted with the need to facilitate growth whilst dealing with important ethical and regulatory challenges arising from new technosciences addressing human health and the environment. Such activities present special opportunities and threats to emerging economies such as those in Central and Eastern Europe (CEE). Countries transitioning from state-run to free market economies are confronted with the need to engage with new actors within the innovation system, such as transnational corporations and public-private partnerships while finding a place within processes of scientific and academic globalisation. At the same time science throws up new social and ethical dilemmas connected with issues such as genetic databases, drug trials and GM crops. The special issue emerged from a workshop held in Prague in October 2007 funded by Innogen, OSI, PASOS, AstraZeneca and Medon. The workshop attempted to map a number of these dynamics within the region, and explore cases from outside of it that might inform life sciences development.
Special Issue Editor:
Dr Peter Robbins, Deputy Co-Director, ESRC Centre for Social and Economic Research on Innovation in Genomics (Innogen), The Open University
Editorials
Innovation in Central and Eastern Europe: An Editorial
Peter Robbins and Farah Huzair
Editorial Essays
Life Sciences Innovation in Central and Eastern Europe: Conceptual Frameworks and Contributions
Farah Huzair and Peter Robbins
Articles
Go East? Multinational Companies in the Czech Life Sciences
Sergey Filippov and Ionara Costa
Innovative Potential in Hungarian Agricultural Biotechnology and the Evolution of Networks
Farah Huzair
The Rise and Fall of the Estonian Genome Project
Rainer Kattel and Margit Suurna
Alternative IP Mechanisms in Genomic Research
Cheryl Power, Ed Levy, Emily Marden, and Ben Warren
Biopharmaceutical Innovation Capacities – Benchmarking Europe and Implications for CEE
Sibylle Gaisser and Thomas Reiss
